370 related articles for article (PubMed ID: 32350552)
41. [Genetic analysis and prenatal diagnosis of Duchenne or Becker muscular dystrophy].
Zhao W; Jiang N; Li S; Li JS; Miao Y; Liang SY; Yu DY
Zhonghua Fu Chan Ke Za Zhi; 2019 Apr; 54(4):226-231. PubMed ID: 31006187
[No Abstract] [Full Text] [Related]
42. A duchenne muscular dystrophy gene hot spot mutation in dystrophin-deficient cavalier king charles spaniels is amenable to exon 51 skipping.
Walmsley GL; Arechavala-Gomeza V; Fernandez-Fuente M; Burke MM; Nagel N; Holder A; Stanley R; Chandler K; Marks SL; Muntoni F; Shelton GD; Piercy RJ
PLoS One; 2010 Jan; 5(1):e8647. PubMed ID: 20072625
[TBL] [Abstract][Full Text] [Related]
43. Therapeutic potential of proteasome inhibition in Duchenne and Becker muscular dystrophies.
Gazzerro E; Assereto S; Bonetto A; Sotgia F; Scarfì S; Pistorio A; Bonuccelli G; Cilli M; Bruno C; Zara F; Lisanti MP; Minetti C
Am J Pathol; 2010 Apr; 176(4):1863-77. PubMed ID: 20304949
[TBL] [Abstract][Full Text] [Related]
44. Immortalized skin fibroblasts expressing conditional MyoD as a renewable and reliable source of converted human muscle cells to assess therapeutic strategies for muscular dystrophies: validation of an exon-skipping approach to restore dystrophin in Duchenne muscular dystrophy cells.
Chaouch S; Mouly V; Goyenvalle A; Vulin A; Mamchaoui K; Negroni E; Di Santo J; Butler-Browne G; Torrente Y; Garcia L; Furling D
Hum Gene Ther; 2009 Jul; 20(7):784-90. PubMed ID: 19358679
[TBL] [Abstract][Full Text] [Related]
45. Genetic diagnosis of Duchenne and Becker muscular dystrophy using multiplex ligation-dependent probe amplification in Rwandan patients.
Uwineza A; Hitayezu J; Murorunkwere S; Ndinkabandi J; Kalala Malu CK; Caberg JH; Dideberg V; Bours V; Mutesa L
J Trop Pediatr; 2014 Apr; 60(2):112-7. PubMed ID: 24213305
[TBL] [Abstract][Full Text] [Related]
46. Genetic analysis of the dystrophin gene in children with Duchenne and Becker muscular dystrophies.
Zhong J; Xu T; Chen G; Liao H; Zhang J; Lan D
Muscle Nerve; 2017 Jul; 56(1):117-121. PubMed ID: 27750387
[TBL] [Abstract][Full Text] [Related]
47. Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells.
van Deutekom JC; Bremmer-Bout M; Janson AA; Ginjaar IB; Baas F; den Dunnen JT; van Ommen GJ
Hum Mol Genet; 2001 Jul; 10(15):1547-54. PubMed ID: 11468272
[TBL] [Abstract][Full Text] [Related]
48. Transcriptional and epigenetic analyses of the DMD locus reveal novel cis‑acting DNA elements that govern muscle dystrophin expression.
Gherardi S; Bovolenta M; Passarelli C; Falzarano MS; Pigini P; Scotton C; Neri M; Armaroli A; Osman H; Selvatici R; Gualandi F; Recchia A; Mora M; Bernasconi P; Maggi L; Morandi L; Ferlini A; Perini G
Biochim Biophys Acta Gene Regul Mech; 2017 Nov; 1860(11):1138-1147. PubMed ID: 28867298
[TBL] [Abstract][Full Text] [Related]
49. Xanthine oxidase is hyper-active in Duchenne muscular dystrophy.
Lindsay A; McCourt PM; Karachunski P; Lowe DA; Ervasti JM
Free Radic Biol Med; 2018 Dec; 129():364-371. PubMed ID: 30312761
[TBL] [Abstract][Full Text] [Related]
50. miR-146a deficiency does not aggravate muscular dystrophy in mdx mice.
Bronisz-Budzyńska I; Chwalenia K; Mucha O; Podkalicka P; Karolina-Bukowska-Strakova ; Józkowicz A; Łoboda A; Kozakowska M; Dulak J
Skelet Muscle; 2019 Aug; 9(1):22. PubMed ID: 31412923
[TBL] [Abstract][Full Text] [Related]
51. miRNome profiling in Duchenne muscular dystrophy; identification of asymptomatic and manifesting female carriers.
Mousa NO; Sayed AA; Fahmy N; Elzayat MG; Bakry U; Abdellatif A; Zahra WK; Osman A
Biosci Rep; 2021 Sep; 41(9):. PubMed ID: 34472584
[TBL] [Abstract][Full Text] [Related]
52. Severe cardiac involvement with preserved truncated dystrophin expression in Becker muscular dystrophy by +1G>A DMD splice-site mutation: a case report.
Komaki R; Hashimoto Y; Mori-Yoshimura M; Oya Y; Takizawa H; Minami N; Nishino I; Aoki Y; Takahashi Y
J Hum Genet; 2020 Oct; 65(10):903-909. PubMed ID: 32504006
[TBL] [Abstract][Full Text] [Related]
53. [Detection of carriers of Duchenne and Becker muscular dystrophy using the fluorescence in situ hybridization method].
Hermanová M; Lukás Z; Kroupová I; Lukásová E
Cesk Patol; 2002 Jan; 38(1):18-23. PubMed ID: 11933457
[TBL] [Abstract][Full Text] [Related]
54. Current protocol of a research phase I clinical trial of full-length dystrophin plasmid DNA in Duchenne/Becker muscular dystrophies. Part I: rationale.
Thioudellet C; Blot S; Squiban P; Fardeau M; Braun S
Neuromuscul Disord; 2002 Oct; 12 Suppl 1():S49-51. PubMed ID: 12206795
[TBL] [Abstract][Full Text] [Related]
55. Clinical approaches in the treatment of Duchenne muscular dystrophy (DMD) using oligonucleotides.
Bertoni C
Front Biosci; 2008 Jan; 13():517-27. PubMed ID: 17981565
[TBL] [Abstract][Full Text] [Related]
56. Contributions of Japanese patients to development of antisense therapy for DMD.
Matsuo M; Takeshima Y; Nishio H
Brain Dev; 2016 Jan; 38(1):4-9. PubMed ID: 26094594
[TBL] [Abstract][Full Text] [Related]
57. Screening for antisense modulation of dystrophin pre-mRNA splicing.
Dickson G; Hill V; Graham IR
Neuromuscul Disord; 2002 Oct; 12 Suppl 1():S67-70. PubMed ID: 12206799
[TBL] [Abstract][Full Text] [Related]
58. Giovanni Nigro and the Naples's school: historical contribution to the knowledge of heart involvement in Duchenne/Becker muscular dystrophies.
Politano L
Acta Myol; 2020 Dec; 39(4):187-190. PubMed ID: 33458573
[TBL] [Abstract][Full Text] [Related]
59. Duchenne Muscular Dystrophy: From Diagnosis to Therapy.
Falzarano MS; Scotton C; Passarelli C; Ferlini A
Molecules; 2015 Oct; 20(10):18168-84. PubMed ID: 26457695
[TBL] [Abstract][Full Text] [Related]
60. Gene replacement therapies for duchenne muscular dystrophy using adeno-associated viral vectors.
Seto JT; Ramos JN; Muir L; Chamberlain JS; Odom GL
Curr Gene Ther; 2012 Jun; 12(3):139-51. PubMed ID: 22533379
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
